. "Appendix B: What Will We Learn from the FDA Clinical Trials Process and What Will We Still Want to Know About Immunotherapies and Depot Medications to Treat Drug Dependence?." New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington, DC: The National Academies Press, 2004.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions
Owens, S.M., and Mayershohn, M. (1986). Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metabolism and Disposition,14(1), 52-58.
Petrakis, I.L., Carroll, K.M., Nich, C., Gordon, L.T., McCance-Katz, E.F., Frankforter, T., and Rounsaville, B.J. (2000). Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction,95(2), 219-228.
Petry, N.M., and Bickel, W.K. (1998). Polydrug abuse in heroin addicts: A behavioral economic analysis. Addiction,93(3), 321-335.
Pettinati, H.M., Volpicelli, J.R., Kranzler, H.R., Luck, G., Rukstalis, M.R., and Cnaan, A. (2000). Sertraline treatment for alcohol dependence: Interactive effects of medication and alcoholic subtype. Alcoholism, Clinical and Experimental Research,24(7), 1041-1049.
Proksch, J.W., Gentry, W.B., and Owens, S.M. (2000). Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. Journal of Pharmacology and Experimental Therapeutics,292(3), 831-837.
Reh, M. (1998). Changes at FDA may speed drug approval process and increase off-label use. Journal of the National Cancer Institute,90(11), 805-807.
Rosenheck, R., and Kosten, T. (2001). Buprenorphine for opiate addiction: Potential economic impact. Drug and Alcohol Dependence,63(3), 253-262.
Sims, T.H., and Fiore, M.C. (2002). Pharmacotherapy for treating tobacco dependence: What is the ideal duration of therapy? CNS Drugs,16(10), 653-662.
Sindelar, J.L., and Fiellin, D.A. (2001). Innovations in treatment for drug abuse: Solutions to a public health problem. Annual Review of Public Health,22, 249-272.
Singh, P.K., and Richell-Herren, K. (2000). Towards evidence based emergency medicine: Best BETs from the Manchester Royal Infirmary. Flumazenil and suspected benzodiazepine overdose. Journal of Accident and Emergency Medicine,17(3), 214.
Sparenborg, S., Vocci, F., and Zukin, S. (1997). Peripherial cocaine-blocking agents: New medications for cocaine dependence. Drug and Alcohol Dependence,48(3), 149-151.
Srisurapanont, M., and Jarusuraisin, N. (2004). Opioid antagonists for alcohol dependence. In The Cochrane Library (Issue 1). Chichester, England: John Wiley & Sons.
Streeton, C., and Whelan, G. (2001). Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. Alcohol and Alcoholism,36(6), 544-552.
Sullivan, M.A., and Covey, L.S. (2002). Nicotine dependence: The role for antidepressants and anxiolytics. Current Opinion in Investigational Drugs,3(2), 262-271.
Sutherland, G. (2002). Current approaches to the management of smoking cessation. Drugs,62(Suppl 2), 53-61.
Swanson, J.M., and Volkow, N.D. (2002). Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. Behavioural Brain Research,130(1-2), 73-78.
Valentine, J.L., Mayersohn, M., Wessinger, W.D., Arnold, L.W., and Owens, S.M. (1996). Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. Journal of Pharmacology and Experimental Therapeutics,278(2), 709-716.
Volpicelli, J., O’Brien, C., Alterman, A., and Hayashida, M. (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry,49(11), 867-880.
Woolacott, N.F., Jones, L., Forbes, C.A., Mather, L.C., Sowden, A.J., Song, F.J., Raftery, J.P., Aveyard, P.N., Hyde, C.J., and Barton, P.M. (2002). The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: A systematic review and economic evaluation. Health Technology Assessment,6(16), 1-245.
Wright, C., and Moore, R.D. (1990). Disulfiram treatment of alcoholism. American Journal of Medicine,88(6), 647-655.